Incyte Corporation - Common Stock (INCY) stock analysis

INCY · Incyte Corporation - Common Stock

Latest recorded price: USD 120.27

Model-estimated fair value: USD 103.58. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Biotechnology

At $120.27, INCY trades 16.1% above the model's base-case value of $103.58. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $81.93 in the conservative case and $129.60 in the optimistic case, with a valuation confidence score of 55/100. Fiscal 2025 figures: revenue growth 14.8%, free cash flow margin 26.3%, ROIC 63.3%. The model does not flag any risk signals for this company.

Similar companies in Healthcare